Document is current

Article History

Received: 13 July 2022

Accepted: 28 August 2022

First Online: 11 September 2022

Declarations

:

: Hideki Kamiya received lecture fees from Novo Nordisk Pharma, Sanofi, Sumitomo Pharma, Nippon Boehringer Ingelheim, Eli Lilly Japan, Daiichi Sankyo, Ono Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Kowa, Novartis Pharma, MSD, and Sanwa Kagaku Kenkyusho. Jiro Nakamura received lecture fees from MSD, Novo Nordisk Pharma, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Novartis Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical, and Terumo. Hideki Kamiya and Jiro Nakamura received research funding from Eli Lilly Japan, Ono Pharmaceutical, and Kissei Pharmaceutical. Hideki Kamiya and Jiro Nakamura received subsidies or donations from MSD, Ono Pharmaceutical, Sumitomo, Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Japan Tobacco, Novo Nordisk Pharma, and Taisho Pharmaceutical. Hideki Kamiya and Jiro Nakamura received endowed departments by commercial entities from Ono Pharmaceutical, Abbott Japan, Sanwa Kagaku Kenkyusho, Kowa, and Terumo. The remaining authors (E Asano-Hayami, Yoshiaki Morishita, T Hayami, Y Shibata, T Kiyose, S Sasajima, Y Hayashi, M Motegi, M Kato, S Asano, H Nakai-Shimoda, Y Yamada, E Miura-Yura, T Himeno, M Kondo, S Tsunekawa, and Y Kato) declare that they have no conflict of interest.

: This study has been approved by the Institutional Review Board of Aichi Medical University (approval number: 2019–133, approval date: 01/10/2020). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki. Informed consent was obtained by the opt-out methods on the website of Aichi Medical University Hospital ().